Abstract
Introduction: Leber's Optic Hereditary Neuropathy (LHON) is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 1871, the German ophthalmologist Theodor Leber was the first to describe the clinical characteristics of his namesake disease, and through unremitting efforts over the past 100 years, researchers have continued to increase their understanding of LHON. In recent years, using gene therapy, several groups have obtained breakthroughs in the treatment of the disease.
Conclusion: In this article, we will review the challenging journey that researchers faced towards our current understanding of LHON, and describe the transition of gene therapy research for LHON from the bench to bedside.
Keywords: Leber's optic hereditary neuropathy, Gene therapy, Translational medicine, Mitochondrial disease, MT-ND4, Allotopic expression technology.
Current Gene Therapy
Title:The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy
Volume: 17 Issue: 4
Author(s): Yong Zhang, Zhen Tian, Jiajia Yuan, Chang Liu, Hong li Liu, Si Qi Ma and Bin Li*
Affiliation:
- Department of Ophthalmology Shiyan, Hubei University of Medicine - Taihe Hospital, Hubei,China
Keywords: Leber's optic hereditary neuropathy, Gene therapy, Translational medicine, Mitochondrial disease, MT-ND4, Allotopic expression technology.
Abstract: Introduction: Leber's Optic Hereditary Neuropathy (LHON) is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 1871, the German ophthalmologist Theodor Leber was the first to describe the clinical characteristics of his namesake disease, and through unremitting efforts over the past 100 years, researchers have continued to increase their understanding of LHON. In recent years, using gene therapy, several groups have obtained breakthroughs in the treatment of the disease.
Conclusion: In this article, we will review the challenging journey that researchers faced towards our current understanding of LHON, and describe the transition of gene therapy research for LHON from the bench to bedside.
Export Options
About this article
Cite this article as:
Zhang Yong , Tian Zhen , Yuan Jiajia , Liu Chang , Liu li Hong , Ma Qi Si and Li Bin *, The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy, Current Gene Therapy 2017; 17 (4) . https://dx.doi.org/10.2174/1566523218666171129204926
DOI https://dx.doi.org/10.2174/1566523218666171129204926 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements